Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Manitsopoulos, N. Maniatis, I. Nikitopoulou, C. Magkou, A. Armaganidis, A. Kotanidou, S. Orfanos (Athens, Greece). Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice. Eur Respir J 2013; 42: Suppl. 57, 468

Member's Comments

No comment yet.

Related content which might interest you: Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling Source: International Congress 2014 – ILDs 4 Year: 2014 Expression of TGF-β and TGFβ receptors in bleomycin-induced pulmonary fibrosis of rats Source: Eur Respir J 2002; 20: Suppl. 38, 312s Year: 2002 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice Source: International Congress 2016 – ILD pathogenesis Year: 2016 HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside Year: 2012 The role of expression of TLR 4 in bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Pirfenidone attenuates myofibroblast differentiation during insufficient mitophagy Source: International Congress 2016 – IPF pathogenesis Year: 2016 Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Ghrelin protects against bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice Source: Eur Respir J 2005; 25: 708-714 Year: 2005 Interdependence of HIF1alpha /TGFbeta1 activity in induction of pulmonary fibrosis Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Leukotriene (LT)C4 aggravate bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2012 - Asthma and COPD: understanding through mechanisms Year: 2012 Leukotriene (LT)C4 aggravate bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2012 - Fibrogenesis between epithelial injury and fibroblast proliferation Year: 2012 Loss of CARM1 prolongs bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – Animal models: asthma, COPD and beyond Year: 2014 Role of dendritic cells in pulmonary fibrosis in mice Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016